Recent advances of novel targeted therapy for squamous cell carcinoma of the head and neck

摘要: Targeted therapies have proven beneficial for patients suffering from a number of different malignancies, including cancers the head and neck. Cetuximab, monoclonal antibody targeting epidermal growth factor receptor has shown benefit in combination with radiation untreated or as single agent platinum resistant disease. Cetuximab is only targeted currently approved by Federal Drug Administration treatment neck cancer. A other agents promising initial results intracellular tyrosine kinase inhibitors, vascular endothelial receptor, well classes novel therapies. Some data supporting use therapy, not yet cancer, will be presented this review. As our understanding cancer cell signaling pathways increases, potential reduced toxicity improved clinical outcomes become reality.